# Safety and Tolerability Study for T-1201 Injection 100 mg Kit in Patients With Advanced Solid Tumors

> **NCT04866641** · PHASE1 · RECRUITING · sponsor: **Taivex Therapeutics Corporation** · enrollment: 40 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** T-1201 Injection 100 mg Kit

## Key facts

- **NCT ID:** NCT04866641
- **Lead sponsor:** Taivex Therapeutics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-06-24
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-07-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04866641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04866641, "Safety and Tolerability Study for T-1201 Injection 100 mg Kit in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04866641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*